IN-UK-311-3956: TAF Switch Study in HBV/HIV
Research type
Research Study
Full title
IN-UK-311-3956: A Study of the Switch of Tenofovir disoproxil fumarate to Tenofovir alafenamide fumarate and the Effect on Glomerular Function in Chronic Hepatitis B and HIV co-infected individuals.
IRAS ID
212683
Contact name
Kosh Agarwal
Contact email
Sponsor organisation
King's College Hospital NHS Foundation Trust
Eudract number
2017-002385-49
Duration of Study in the UK
0 years, 11 months, 31 days
Research summary
Tenofovir disoproxil fumarate (TDF) is the treatment of choice for hepatitis B infection both in those only infected with hepatitis B and also those infected with HIV as well. The use of TDF for the treatment of hepatitis B/HIV has been associated with reductions in kidney function. Tenofovir alafenamide fumarate (TAF) is a medication that is converted to active tenofovir in the blood and is associated with at least equal effectivness against both HIV and hepatitis B infections but with the advantage of less adverse effects on kidney function and bone mineral density.It has been shown to be effective in treating HIV infected and HBV infected indivuduals but there are fewer data on its use in individuals infected with both HIV and HBV. This study is an exploratory pilot study that aims to further assess the safety and efficacy of TAF in HIV/HBV individuals.
REC name
North East - Newcastle & North Tyneside 2 Research Ethics Committee
REC reference
17/NE/0301
Date of REC Opinion
27 Nov 2017
REC opinion
Further Information Favourable Opinion